Brain scans and genes may guide better schizophrenia drug choices
NCT ID NCT06969755
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people aged 18-35 experiencing their first episode of psychosis. Researchers will use genetic tests and MRI brain scans to see if certain markers can predict which antipsychotic drug (aripiprazole, risperidone, or clozapine) will work best. The goal is to improve symptom relief and reduce side effects like weight gain. Participants will be followed for 12 weeks to compare how well each drug works based on their individual biology.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aripiprazole, risperidone, and clozapine (antipsychotic drugs)
What this could lead to
If successful, this could help doctors choose the right medication for early schizophrenia based on a patient's genetics and brain scans, leading to better symptom control and fewer side effects.
What could go wrong
This is a Phase 4 study with 180 participants, so results may not apply to everyone. The genetic and brain scan markers are still experimental, and the drugs have known risks like weight gain and blood cell problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre for Addiction and Mental Health
RECRUITINGToronto, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Feinstein Institute for Medical Research
RECRUITINGGlen Oaks, New York, 11004, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
McLean
RECRUITINGBelmont, Massachusetts, 02478, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California San Diego
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••